Serina Therapeutics (FRA:2BO) Shares Outstanding (EOP): 14.90 Mil (As of Mar. 2026)


FRA:2BO Serina Therapeutics Inc FRA:2BO
14 GF Score
Price €1.48
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Shares Outstanding (EOP)?

Serina Therapeutics FRA:2BO +8.03% 14 Shares Outstanding (EOP) is 14.90 Mil as of Mar. 2026. GuruFocus rates FRA:2BO with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Serina Therapeutics's shares outstanding for the quarter that ended in Mar. 2026 was 14.90 Mil.

Serina Therapeutics's quarterly shares outstanding increased from Dec. 2025 (10.77 Mil) to Mar. 2026 (14.90 Mil). It means Serina Therapeutics issued new shares from Dec. 2025 to Mar. 2026 .

Serina Therapeutics's annual shares outstanding increased from Dec. 2024 (9.42 Mil) to Dec. 2025 (10.77 Mil). It means Serina Therapeutics issued new shares from Dec. 2024 to Dec. 2025 .


Serina Therapeutics  (FRA:2BO) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Serina Therapeutics Shares Outstanding (EOP) Related Terms


Serina Therapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Shares Outstanding (EOP) Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
8.41 8.41 8.41 9.42 10.77

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.93 10.15 10.54 10.77 14.90

FRA:2BO vs NRSN, IGC, PVCT: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Serina Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Shares Outstanding (EOP) falls into.


FRA:2BO
14GF Score
Serina Therapeutics Inc FRA:2BO
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 14.90 Mil mean?
Serina Therapeutics (FRA:2BO) has a Shares Outstanding (EOP) of 14.90 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Serina Therapeutics and its competitors.
Is Serina Therapeutics' Shares Outstanding (EOP) too high?
Serina Therapeutics' current Shares Outstanding (EOP) is 14.90 Mil. Overall, Serina Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Shares Outstanding (EOP) compare to NRSN and IGC?
Serina Therapeutics' Shares Outstanding (EOP) of 14.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Serina Therapeutics and its competitors. Serina Therapeutics's current Shares Outstanding (EOP) is 14.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (FRA:2BO) has a current Shares Outstanding (EOP) of 14.90 Mil. The current Shares Outstanding (EOP) is 14.90 Mil. Serina Therapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Serina Therapeutics (FRA:2BO), the current Shares Outstanding (EOP) is 14.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges SER:USA
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
14GF Score

Get the complete analysis for FRA:2BO

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.48
Price